Keyphrases
Executive Function
100%
EpiTrack
70%
Drug-resistant Epilepsy
66%
Mild Traumatic Brain Injury (mTBI)
66%
Resilience
66%
Vagus Nerve Stimulation
51%
Vagus Nerve Stimulation Therapy
40%
Digit Span Backwards
33%
Trail Making Test
33%
Refractory Epilepsy
33%
Attention Function
33%
Hormone Therapy
33%
Menopausal Symptoms
33%
Multiple Sclerosis
33%
Depressive Symptoms
23%
Resilience Scale
21%
Menopausal Hormone Therapy
20%
Antiepileptic Drugs
20%
Epilepsy Patients
17%
Psychiatric Comorbidity
17%
Insomnia Symptoms
17%
Antiseizure Medication
14%
Follow-up Interval
14%
Confidence Interval
13%
Vasomotor Symptoms
12%
Insomnia
10%
Linear Mixed Model
10%
Paced Auditory Serial Addition Test (PASAT)
10%
Drug Burden
10%
Deep Brain Stimulation
10%
Pain Symptoms
9%
Self-reported Fatigue
9%
Orthopedics
8%
Post-concussion Syndrome
8%
Executive Attention
7%
Beck Depression inventory-II (BDI-II)
7%
Stimulation Protocol
7%
Quality of Life
6%
Group-based
6%
Drug Groups
6%
Cognitive Performance
5%
Symptom Prevalence
5%
Insomnia Severity Index
5%
Medicine and Dentistry
Executive Function
66%
Drug Resistant Epilepsy
66%
Vagus Nerve Stimulation
66%
Stimulation Therapy
40%
Menopausal Symptom
33%
Multiple Sclerosis
33%
Hormone Therapy
33%
Trail Making Test
33%
Drug Therapy
22%
Comorbidity
21%
Vasomotor
12%
Paced Auditory Serial Addition Test
10%
Depression
7%
Working Memory
6%
COVID-19
5%
Patient with Epilepsy
5%
Neuroscience
Executive Function
100%
Vagus Nerve Stimulation
71%
Stimulation Therapy
44%
Multiple Sclerosis
33%
Intractable Epilepsy
33%
Hormone Therapy
33%
Anticonvulsant
33%
Comorbidity
27%
Antiseizure Medication
22%
Electrical Brain Stimulation
14%
Vasomotor
12%
Working Memory
11%
Paced Auditory Serial Addition Test
10%
Depression
7%
Cognitive Tests
5%
